These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 37570656)

  • 1. Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors.
    Frühauf A; Behringer M; Meyer-Almes FJ
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An insight into therapeutic efficacy of heterocycles as histone-modifying enzyme inhibitors that targets cancer epigenetic pathways.
    Basha NJ; Basavarajaiah SM
    Chem Biol Drug Des; 2022 Nov; 100(5):682-698. PubMed ID: 36059065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Overview of the Biological Evaluation of Selected Nitrogen-Containing Heterocycle Medicinal Chemistry Compounds.
    Ebenezer O; Jordaan MA; Carena G; Bono T; Shapi M; Tuszynski JA
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update.
    Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A
    Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.
    Dinarello CA; Fossati G; Mascagni P
    Mol Med; 2011; 17(5-6):333-52. PubMed ID: 21556484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy.
    Rusu A; Moga IM; Uncu L; Hancu G
    Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-targeted histone deacetylase inhibitors in cancer therapy.
    Ai T; Cui H; Chen L
    Curr Med Chem; 2012; 19(4):475-87. PubMed ID: 22204328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).
    He X; Hui Z; Xu L; Bai R; Gao Y; Wang Z; Xie T; Ye XY
    Eur J Med Chem; 2022 Jan; 227():113946. PubMed ID: 34775332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide based macrocycles: selective histone deacetylase inhibitors with antiproliferative activity.
    Rajak H; Singh A; Dewangan PK; Patel V; Jain DK; Tiwari SK; Veerasamy R; Sharma PC
    Curr Med Chem; 2013; 20(14):1887-903. PubMed ID: 23409715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and Stability of Aromatic Nitrogen Heterocycles Used in the Field of Energetic Materials.
    Zong HH; Yao C; Sun CQ; Zhang JG; Zhang L
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32679862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics.
    Tasneem S; Alam MM; Amir M; Akhter M; Parvez S; Verma G; Nainwal LM; Equbal A; Anwer T; Shaquiquzzaman M
    Mini Rev Med Chem; 2022; 22(12):1648-1706. PubMed ID: 34939540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds.
    Leśniewska A; Przybylski P
    Eur J Med Chem; 2024 Sep; 275():116556. PubMed ID: 38879971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
    Carrillo AK; Guiguemde WA; Guy RK
    Bioorg Med Chem; 2015 Aug; 23(16):5151-5. PubMed ID: 25637120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
    Kollar J; Frecer V
    J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylase Inhibitors in Tumor Immunotherapy.
    Zhao LM; Zhang JH
    Curr Med Chem; 2019; 26(17):2990-3008. PubMed ID: 28762309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.
    Geurs S; Clarisse D; De Bosscher K; D'hooghe M
    J Med Chem; 2023 Jun; 66(12):7698-7729. PubMed ID: 37276138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory potential of nitrogen, oxygen and sulfur containing heterocyclic scaffolds against acetylcholinesterase and butyrylcholinesterase.
    Obaid RJ; Naeem N; Mughal EU; Al-Rooqi MM; Sadiq A; Jassas RS; Moussa Z; Ahmed SA
    RSC Adv; 2022 Jul; 12(31):19764-19855. PubMed ID: 35919585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.